Gilead Sciences, Inc (0QYQ) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Gilead Sciences, Inc $220, price $147, upside +50.0%, quality 73 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range $49.20 – $154.59 · fair‑value band $129.04 – $275.51 · the $146.50 price screens below the $219.79 fair value. Dashed = 300-day average. As of Sep 29, 2026.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Show more
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Stock analysis
Gilead Sciences, Inc (0QYQ) currently trades at $146.50, while our model-based Fair Value estimate is $219.79, implying the stock looks roughly 33.3% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $247.78 per share, and 17 of the 25 models we run sit above the $146.50 price.
Bear case: the Asset-Based group reads lowest at $26.15, and 8 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: $129.04 (bear) to $275.51 (bull), the price of $146.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Gilead Sciences, Inc reported revenue of $27.3B in FY2021 versus $26.1B in FY2017, a compound +1.1%/yr. Reported net income was $6.2B in FY2021, compounding +7.7%/yr from FY2017.
Key figures
Market cap $80.2B · P/S ratio 2.70 · Dividend yield 2.2% · Net margin 22.8% · Return on equity 43.4% · Return on assets (EBIT) 12.1% · Operating margin 39.3% · Revenue (TTM) $29.7B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (medium confidence).
What moves the price
The share trades about 5% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 50%, 0QYQ screens cheaper than that median.
Fair Value models
Bear $129.04Fair Value $219.79Bull $275.51
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
’17
’18
’19
’20
’21
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
54.1% (2017) → 36.3% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Gilead Sciences, Inc (0QYQ) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of $219.79 versus a price of $146.50, about +50% upside (undervalued).
What is the fair value of 0QYQ?
Our model-based fair value for Gilead Sciences, Inc is $219.79 (as of Sep 29, 2026), built from audited fundamentals. The current price: $146.50.
What is the quality score of 0QYQ?
Gilead Sciences, Inc has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gilead Sciences, Inc (0QYQ)?
Our model-based price target is the fair value of $219.79 (as of Sep 29, 2026) from 25 valuation models. Cautious scenario $129.04, optimistic scenario $275.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Gilead Sciences, Inc stock forecast for 2026?
Our models put fair value at $219.79, about +50% upside versus a price of $146.50 (undervalued). Cautious scenario $129.04, optimistic scenario $275.51. The calculation is refreshed regularly with new filings.
What is the revenue of Gilead Sciences, Inc (0QYQ)?
Gilead Sciences, Inc reported trailing-twelve-month revenue of about $29.7B (latest available figure, as of Sep 29, 2026).
Does Gilead Sciences, Inc pay a dividend?
Gilead Sciences, Inc currently shows a dividend yield of about 2.18% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of Gilead Sciences, Inc (0QYQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gilead Sciences, Inc it is $219.79 per share (as of Sep 29, 2026), against a price of $146.50. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Gilead Sciences, Inc stock overvalued or undervalued in 2026?
As of Sep 29, 2026, 0QYQ trades below its calculated fair value: price $146.50, fair value $219.79, a gap of about +50% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QYQ?
No. The price is what the market pays today ($146.50); the fair value is what the company's own numbers justify ($219.79). For Gilead Sciences, Inc the two are $73.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gilead Sciences, Inc worth?
The market values Gilead Sciences, Inc at about $80.2B (market capitalisation, as of Sep 29, 2026). Per share that is $146.50; our models calculate a fair value of $219.79 per share.
What do the bullish and bearish scenarios say about 0QYQ?
Our models span a range for Gilead Sciences, Inc: cautious scenario $129.04, base $219.79, optimistic $275.51 per share (as of Sep 29, 2026, price $146.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0QYQ from its 52-week high?
Gilead Sciences, Inc trades at $146.50, about 5% below its 52-week high of $154.59 and 35% above the low of $108.21 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $219.79 is for.
Which stocks are comparable to Gilead Sciences, Inc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gilead Sciences, Inc stock attractive at the current price?
The data as of Sep 29, 2026: price $146.50, calculated fair value $219.79 (+50%), Quality Score 73/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QYQ calculated?
We run Gilead Sciences, Inc through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $219.79, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Gilead Sciences, Inc currently trades 33 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gilead Sciences, Inc (0QYQ)?
The closing price on Oct 2, 2026 was $146.50. Our model-based fair value is $219.79, about +50% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gilead Sciences, Inc right now?
The rarer combination: high quality (73/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range ($129.04 to $275.51) leaves room in how you read the outcome.
Key figures of Gilead Sciences, Inc
How large is the market capitalisation of Gilead Sciences, Inc (0QYQ)?
The market capitalisation of Gilead Sciences, Inc is $80.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gilead Sciences, Inc (0QYQ)?
The price-to-sales ratio of Gilead Sciences, Inc is 2.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Gilead Sciences, Inc (0QYQ)?
The dividend yield of Gilead Sciences, Inc is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Gilead Sciences, Inc (0QYQ)?
The net margin of Gilead Sciences, Inc is 22.8% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gilead Sciences, Inc (0QYQ)?
The return on equity (ROE) of Gilead Sciences, Inc is 43.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gilead Sciences, Inc (0QYQ)?
On an EBIT basis the return on assets of Gilead Sciences, Inc is 12.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gilead Sciences, Inc (0QYQ)?
The operating margin of Gilead Sciences, Inc is 39.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gilead Sciences, Inc (0QYQ)?
Revenue at Gilead Sciences, Inc is growing +4.4% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gilead Sciences, Inc (0QYQ)?
Earnings per share at Gilead Sciences, Inc are growing +54.8% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
